The Journal of Immunology, Vol 150, Issue 3 763-770, Copyright © 1993 by American Association of Immunologists

ARTICLES

The fate of anergic T cells in vivo

K Migita and A Ochi
Division of Neurobiology and Molecular Immunology, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.

The kinetics of Staphylococcal enterotoxin B-(SEB) induced peripheral tolerance has been investigated. Ten days after SEB injection, thymectomized BALB/cByJ mice showed suppressed spleen cell proliferative responses to SEB. After 2 mo the SEB-specific response was partly recovered. Four months later the response of spleen cells of SEB-primed mice was comparable to those of control mice. The proportion of CD4+, V beta 8+ T cells was diminished in the tolerized mice and was not restored even after the response was recovered. Purified CD4+, V beta 8+ T cells from SEB-primed mice after 4 mo responded similarly to SEB as control CD4+, V beta 8+ T cells. These expressed a similar profile of surface markers compared with that of unprimed control cells, except a homing receptor was slightly lower. An experiment that addressed the possibility that non-anergic T cells expand over time and are in fact responsible for the recovery of the proliferative response showed that such events unlikely occur in vivo. Therefore, the data indicate that T cell anergy is reversible in vivo. It is also suggested that the challenge with superantigen results in neither clonal expansion nor specific CD4+, V beta 8+ T cell memory.

This article has been cited by other articles:

				Z. Illes, H. Waldner, J. Reddy, E. Bettelli, L. B. Nicholson, and V. K. Kuchroo T Cell Tolerance Induced by Cross-Reactive TCR Ligands Can Be Broken by Superagonist Resulting in Anti-Inflammatory T Cell Cytokine Production J. Immunol., August 1, 2005; 175(3): 1491 - 1497. [Abstract] [Full Text] [PDF]

				C. Ohlen, M. Kalos, L. E. Cheng, A. C. Shur, D. J. Hong, B. D. Carson, N. C.T. Kokot, C. G. Lerner, B. D. Sather, E. S. Huseby, et al. CD8+ T Cell Tolerance to a Tumor-associated Antigen Is Maintained at the Level of Expansion Rather than Effector Function J. Exp. Med., June 3, 2002; 195(11): 1407 - 1418. [Abstract] [Full Text] [PDF]

				C. Ohlen, M. Kalos, D. J. Hong, A. C. Shur, and P. D. Greenberg Expression of a Tolerizing Tumor Antigen in Peripheral Tissue Does Not Preclude Recovery of High-Affinity CD8+ T Cells or CTL Immunotherapy of Tumors Expressing the Antigen J. Immunol., February 15, 2001; 166(4): 2863 - 2870. [Abstract] [Full Text] [PDF]

				G. Lombardi, P. J. Dunne, D. Scheel-Toellner, T. Sanyal, D. Pilling, L. S. Taams, P. Life, J. M. Lord, M. Salmon, and A. N. Akbar Type 1 IFN Maintains the Survival of Anergic CD4+ T Cells J. Immunol., October 1, 2000; 165(7): 3782 - 3789. [Abstract] [Full Text] [PDF]

				A. Attinger, H. Acha-Orbea, and H. R. MacDonald Cutting Edge: Cell Autonomous Rather Than Environmental Factors Control Bacterial Superantigen-Induced T Cell Anergy In Vivo J. Immunol., August 1, 2000; 165(3): 1171 - 1174. [Abstract] [Full Text] [PDF]

				Y. Nakata, A. Uzawa, and G. Suzuki Control of CD4 T cell fate by antigen re-stimulation with or without CTLA-4 engagement 24 h after priming Int. Immunol., April 1, 2000; 12(4): 459 - 466. [Abstract] [Full Text] [PDF]

				H. Kawasaki1, Y. Nakata, G. Suzuki, K. Chihara, T. Tokuhisa, and S. Shiozawa Increased c-Fos/activator protein-1 confers resistance against anergy induction on antigen-specific T cell Int. Immunol., December 1, 1999; 11(12): 1873 - 1880. [Abstract] [Full Text] [PDF]

				K. A. Pape, R. Merica, A. Mondino, A. Khoruts, and M. K. Jenkins Direct Evidence That Functionally Impaired CD4+ T Cells Persist In Vivo Following Induction of Peripheral Tolerance J. Immunol., May 15, 1998; 160(10): 4719 - 4729. [Abstract] [Full Text] [PDF]

				Z. Grossman and A. Singer Tuning of activation thresholds explains flexibility in the selection and development of T cells in the thymus PNAS, December 10, 1996; 93(25): 14747 - 14752. [Abstract] [Full Text] [PDF]